Product Description
GlaxoSmithKline is developing GSK-2556286 as a treatment for Tuberculosis. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04472897)
Mechanisms of Action: Cholesterol Synthesis Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Tuberculosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04472897 |
NCT04472897 | P1 |
Terminated |
Tuberculosis |
2024-11-06 |
50% |
2025-05-13 |
Primary Endpoints |